Form 8-K Adaptimmune Therapeutics For: Nov 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Adaptimmune Therapeutics (ADAP) Tops Q3 EPS by 2c
November 10, 2016 6:33 AM ESTAdaptimmune Therapeutics (NASDAQ: ADAP) reported Q3 EPS of ($0.26), $0.02 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $5.32 million.
For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.
... More